The peel formulation gets the attention in most protocol discussions. The step before it, cleansing, gets a line in the SOP and nothing more: cleanse, pat dry, proceed. That order of attention does not match the mechanism. What is sitting on the skin when the active step begins determines how evenly that active makes contact, and a peel that never touches the surface evenly cannot renew it evenly either.
Sebum and the residue from whatever was applied last are not inert. They sit between the active and the stratum corneum as a physical layer, and the active distributes exactly as evenly as that layer allows. The question worth asking about a prep cleanser is not only whether it cleans, but what it leaves behind and what it does to the skin on the way there.
Residual film turns an even peel into an uneven one
A peel applied over an uneven surface does not land evenly, full stop. Sebum thickness varies across the face, and product film from a previous step adds another inconsistent layer on top of it. The active contacts thinner, cleaner patches of skin more readily than it contacts areas still carrying residue.
The practical consequence shows up downstream, not at the prep step itself. An operator compensates for an uneven first pass by working a second time over the areas that look like they took less, which is functionally going deeper to correct unevenness the cleanse should have prevented. That is the opposite of what a fourth-generation peel is built to avoid: renewal driven by adsorbing and removing inflammation-inducing substances, not by driving deeper into tissue to force a uniform result.
pH is a barrier decision, not a side detail
Removing residue is only half the cleanser’s job. Whatever the formulation does to the skin’s surface while it removes that residue carries into the next step, because the active is applied to whatever state the cleanser leaves behind.
A high-alkaline cleanser lifts lipids aggressively and pushes the skin surface away from its resting state before anything active has even been applied. That is a cost paid at the wrong point in the sequence: the prep step is supposed to clear the way for the active, not introduce its own disturbance for the active step to then work around. A prep formulation that stays closer to a neutral range is making a narrower claim for itself: clean the surface, disturb it as little as possible, and get out of the way.
What a neutral, micro-bubble formulation is doing differently
LHALA Foam is a neutral micro-bubble prep cleanser formulated at pH 5.5 to 7.5, in a 300mL format. The micro-bubble mechanism is built to lift surface residue mechanically rather than relying on a more aggressive surfactant load to do the same job, and the pH band is the second half of the same design intent: clean the surface without pushing it into an alkaline state ahead of the active step.
What supports what. LHALA Foam’s formulation facts on file are the neutral micro-bubble mechanism and the pH 5.5 to 7.5 range; no product-specific irritation or efficacy test has been supplied for U.S. review, so those facts stand as formulation specification, not as a tested outcome claim. LHALA Peel Basic and Ultra each completed their own skin irritation test, 30 volunteers per format, non-irritant result; that testing is specific to the peel formats and does not extend to the prep cleanser.
Reading a prep cleanser’s spec before you pair it with any peel
A pH number on a data sheet is only useful if you know what it is describing. Ask whether the figure is the formulation’s as-packaged pH or the in-use pH once it is diluted and worked into the skin, since suppliers sometimes quote the more flattering of the two. Ask what the cleansing mechanism is, surfactant-led or mechanical, because that changes how much the formulation leans on its pH to avoid stripping lipids. And ask the same question you would ask about any other product in the line: what testing exists for this specific item, and what is manufacturer specification rather than a measured result.
That last question matters more for a prep step than it might seem. A cleanser is easy to treat as a commodity because it is not the product doing the visible work. Treating it that way is how a protocol ends up with an active step built around barrier preservation and a prep step that undoes part of that work before the active is even on the skin.
Build the sequence as a sequence
None of this changes with a single swap. It changes when the prep step is evaluated with the same questions applied to the active step: what does it do mechanically, what does its chemistry do to the barrier, and what is documented versus declared. A protocol built on the Korean glass-skin standard treats barrier health as a requirement running through every stage, prep included, rather than a property of the active product alone.
If you are evaluating a Korean peel line for your menu and want the formulation specs and testing status for the prep step alongside the active, the U.S. team can send what is on file for each product and flag what is still pending.